🔗 Share this article

As the US continues making unprecedented revisions to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by questioning coronavirus shots throughout the pandemic and has focused upon potential deaths after Covid vaccination in her brief position at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Schedule

Health officials planned to reveal sweeping revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US at odds with much of the global community with insufficient data for public health gain. This reveal has been pushed back until the new year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to address the audience at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this year.

A Shift at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the agency – and it points to a increased emphasis upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific childhood shot schedules in the US to become more like Denmark's approach, a society with universal health coverage and a citizenry roughly the size of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccination policy – typically the purview of Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Qualifications

Høeg has little discernible experience in medication creation, approval processes or leadership, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“She appears not to have the requisite experience” for running the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a major agency. She lacks background in industry regulation.”

Former commissioners of CBER would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that previous people who headed the center have had.”

This division has an immense range of responsibilities at the agency, she stated.

“The public just focuses on the new drug program, but the generic drug division clears numerous generic medications. There’s a biologic copycat branch, over-the-counter program and more, and all of those must be looked after,” Dr. Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a significant management aspect to the position, which oversees over 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official said.

Response and Contentious Programs

Regarding questions about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among agency officials on immunizations, a press secretary said that the “questions are based on inaccurate presumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson said, pointing to the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial one-day therapy clearance system that allegedly concerned her preceding directors. “By what process are these drugs being chosen for this voucher program? Who is making the decisions?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he said, “the agency seems to be moving towards laxer oversight of most medications, with the exception of immunizations.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if troubling, past, critics have noted. She published a study using non-validated public submissions to determine the rate of heart inflammation following COVID-19 immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are riskier than they are.

Among her “policy goals” for the incoming federal leadership featured altering guidelines for new vaccines and halting “optional” immunizations, she remarked post-election on a audio program. At the FDA, Høeg has according to sources suggested excluding teenage boys from getting COVID-19 vaccines.

“She’s an thorough ideologue who begins with her conclusions and tailors the evidence to retrofit the science in a very deceptive, untruthful manner,” Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined other skeptics, {like|